Uday R Popat
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Uday R Popat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04859946 · Itacitinib for the Prevention of Graft Versus Host DiseaseM.D. Anderson Cancer Center · active not recruiting · Hematologic and Lymphocytic Disorder · principal investigator
- Ph2/Ph3NCT04708054 · Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT04127721 · Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationM.D. Anderson Cancer Center · withdrawn · Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph1/Ph2NCT03247088 · Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center · active not recruiting · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT02861417 · Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center · active not recruiting · Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome · principal investigator
- Ph2NCT02250937 · Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1NCT01300611 · TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTarix Pharmaceuticals · terminated · Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:14 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.J Clin Oncol · 2022116 citationsRCR 7.6
- 10 citationsRCR 0.3
- A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.Bone Marrow Transplant · 202210 citationsRCR 0.7
- Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.Transplant Cell Ther · 20219 citationsRCR 0.5
- 7 citationsRCR 0.3